1.
Chem Commun (Camb)
; 58(12): 1962-1965, 2022 Feb 08.
Article
En
| MEDLINE
| ID: mdl-35044383
The development of divinylpyrimidine (DVP) reagents for the synthesis of antibody-drug conjugates (ADCs) with in vivo efficacy and tolerability is reported. Detailed structural characterisation of the synthesised ADCs was first conducted followed by in vitro and in vivo evaluation of the ADCs' ability to safely and selectively eradicate target-positive tumours.
Antineoplastic Agents, Immunological/pharmacology , Immunoconjugates/chemistry , Indicators and Reagents/chemistry , Pyrimidines/chemistry , Animals , Antineoplastic Agents, Immunological/adverse effects , Cell Line, Tumor , Humans , Immunoconjugates/adverse effects , Mice , Proof of Concept Study , Trastuzumab/adverse effects , Trastuzumab/pharmacology , Xenograft Model Antitumor Assays